Takeda Pharmaceutical SWOT Analysis, USP & Competitors

Posted in Pharmaceuticals and Healthcare, Total Reads: 2535

SWOT Analysis of Takeda Pharmaceutical with USP, Competition, STP (Segmentation, Targeting, Positioning) - Marketing Analysis

Takeda Pharmaceutical

Parent Company

Takeda Pharmaceutical




Health Care

Tagline/ Slogan

Transformation into a New Takeda


The largest pharmaceutical company in Japan and one of the global leaders of the industry



Metabolic, CNS, Inflammatory diseases  & oncology

Target Group

Healthcare professionals & pharmacists.


Takeda is committed to striving towards better health for patients worldwide through leading innovation in medicine.

SWOT Analysis


1. Merger with Zydus enhanced brand position

2. Profitable position as the largest drug maker in Japan and global presence in nearly 25 countries

3. Takeda effect in which sales & marketing work closely to revitalize product showing flat sales

4. Strong product pipeline and over 36,000 employees

5. Good positioning in endocrinology market


1. Largely dependent on its four blockbuster therapeutics

2. Product recalls & discontinued projects have earlier affected image

3. Limited presence in emerging markets


1. It can enhance its positioning in monoclonal antibody development

2. It can enter India’s increasing generic market

3. Increasing standards  of living


1. Japanese health care reforms encouraging generic prescribing

2. Increased penetration of western players in Japanese market

3. Natural calamities in Japan



1. Abbot laboratories
2. AstraZeneca

3. Astellas Pharma Inc

4. Lupin

5. Cipla


Looking for More Brands? Search BrandGuide

Edit the Brand or Add a New One : Contribute to BrandGuide

The brandnames and other brand information used in the brandguide section are properties of their respective companies. The companies are not associated with MBASkool in any way. The brand names are used purely for educational/academic purpose only.
Utmost Care has been taken in the analysis of the brands. However, if you find any ambiguity kindly help us improve.